Humira: lessons from 20 years of patents, pricing and profits

21-03-2023

Sarah Speight

Humira: lessons from 20 years of patents, pricing and profits

MJgraphics / Shutterstock.com

As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Biotech multinational AbbVie has long reigned supreme in the biologics marketplace.

But the mastermind of blockbuster drug Humira has come under intense scrutiny of late over its pricing and patent strategies.

Brought to market in 2003, the anti-inflammatory drug has dominated the market for two decades.


Humira, AbbVie, patents, drug pricing, patent walls, biosimilars, biotech, pharma

LSIPR